Leerink Partnrs Analysts Decrease Earnings Estimates for Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Analysts at Leerink Partnrs dropped their Q4 2024 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a research note issued to investors on Monday, August 5th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings per share of $1.38 for the quarter, down from their previous forecast of $1.42. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.23) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics’ FY2027 earnings at $1.50 EPS and FY2028 earnings at $2.55 EPS.

Several other equities analysts also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Friday. StockNews.com downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 22nd. Finally, Oppenheimer reiterated an “outperform” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Monday, May 6th.

Aldeyra Therapeutics Stock Up 21.7 %

ALDX traded up $0.91 during trading on Thursday, hitting $5.10. The company’s stock had a trading volume of 2,333,130 shares, compared to its average volume of 504,526. The firm’s 50 day moving average price is $3.68 and its two-hundred day moving average price is $3.65. Aldeyra Therapeutics has a 12 month low of $1.42 and a 12 month high of $7.88. The stock has a market capitalization of $303.01 million, a price-to-earnings ratio of -10.00 and a beta of 1.45.

Institutional Investors Weigh In On Aldeyra Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ALDX. SG Americas Securities LLC acquired a new stake in shares of Aldeyra Therapeutics in the 4th quarter valued at $39,000. International Assets Investment Management LLC grew its stake in shares of Aldeyra Therapeutics by 319.2% during the fourth quarter. International Assets Investment Management LLC now owns 205,335 shares of the biotechnology company’s stock worth $7,210,000 after purchasing an additional 156,353 shares during the period. Prime Capital Investment Advisors LLC acquired a new stake in shares of Aldeyra Therapeutics during the fourth quarter worth $35,000. Strs Ohio grew its stake in shares of Aldeyra Therapeutics by 270.8% during the fourth quarter. Strs Ohio now owns 87,500 shares of the biotechnology company’s stock worth $307,000 after purchasing an additional 63,900 shares during the period. Finally, Cornercap Investment Counsel Inc. acquired a new stake in shares of Aldeyra Therapeutics during the fourth quarter worth $216,000. 59.71% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.